| Name of Individual  | Individual's Role(s) inc <b>a</b> ivity         | Name of heligible Ompany(s) | Other Relationships | Nature of Relevant Financial Relationship(s) |  |
|---|---|-----------------------------|---------------------|--|--|
| (e.g. #anner, Reviewe&peaker, Athor, Moderator, Binelist) |   |                             |                     |  |  |
| Diago MrianeVT: 0.007Tw/ A)T: (                           | 0.007 T24 0 Td [(in) + 0.0007 (r) 2E6 (in) = 2r |                             |                     |  |  |

Diego Adrian6YTj -0.007Tw (A)Tj -0.007 T34 0 Td [(in)-1.69697 (r)-2E6 (v)5.3r,

| Brian Hill        | Speaker         | Abbvie, Astrazeneca, Beigene, Genentech, Gilead,<br>Seattle Genetics  |  | ConsultancyAbbvie, Astrazeneca, Beigene, Genentech, Gilead, Seattle<br>Genetics<br>Honoraria:Abbvie, Astrazeneca, Beigene, Genentech, Gilead, Seattle G¢<br>Research Funding: Abbvie, Astrazeneca, Beigene, Gilead, Seattle Genetics   |
|-------------------|-----------------|---|--|--|
| Shernan Holtan    | Speaker         | CSL Behring, Ossium, Sanofi/Kadmon, Incyte, Vitra   |  | ConsultancyCSL Behring, Ossium, Sanofi/Kadmon  |
| Anthony Hunter    | Speaker         | Therapeutics<br>Ascentage Pharma, Blueprint Medicines, Cogent<br>Biosciences, GSK, Incyte, PharmaEssentia, Incyte,<br>Novartis, PharmaEssentia, Syntrix Biosystems              |  | Research Funding: Incyte, Vitrac Therapeutics<br>Research Funding: Ascentage Pharma, Blueprint Medicines, Cogent<br>Bioscience©onsultancyCogent Biosciences<br>Membership on a Board or Advisory Committee: GSK, Incyte,<br>PharmaEssentiBesearch Funding: Incyte, Novartis, PharmaEssentia, Syntrix<br>Biosvstems |
| Seethal A. Jacob  | Speaker         |   | earch Funding: NIH NHLBI<br>3HL143162      | Membership on a Board or Advisory Committee: Global Blood Therapeu   |
| Jonathan Kaufman  | Planner/Speaker | Abbvie, BMS, Sanofi, Incyte, Novartis   |  | ConsultancyAbbvie, BMS, Sanofi<br>Membership on a Board or Advisory Committelencyte<br>Research Fundindncyte, Novartis   |
| Ashwin Kishtagari | Speaker         | CTI Biopharm Corp, Geron Corporation, Servier<br>Pharmaceuticals  |  | Speakers Bureau: CTI Biopharm Corp, Geron Corporation<br>Membership on a Board or Advisory Committeeervier Pharmaceuticals   |
| Adam Kittai       | Speaker         | Abbvie, AstraZeneca, Beigene, Bristol-Myers Squibl<br>Lilly, AstraZeneca, Beigene   |  | Consultancy: Abbvie, AstraZeneca, Beigene, Bristol-Myers Squibb<br>Membership on a Board or Advisory CommitteEti-Lilly<br>Research Funding: AstraZeneca, Beigene, Bristol-Myers Squibb   |
| Kevin Kuo         | Speaker         | Agios Pharmaceuticals, Alexion Pharmaceuticals, B<br>Myers Squibb, Novo Nordisk, Pfizer, Vertex<br>Pharmaceuticals, Agios Pharmaceuticals,<br>]}À Œ š]Àl^ ν}(]l^ νP u}U W νμυ Œ |  | ConsultancyAgios Pharmaceuticals, Alexion Pharmaceuticals, Bristol-My<br>Squibb, Novo Nordisk, Pfizer, Vertex Pharmaceuticals<br>Research FundingAgios Pharmaceuticals, Bioverativ/Sanofi/Sangamo<br>Membership on a Board or Advisory Committe®enumbra  |
| Ang Li            | Speaker         | N/a   |  | Nothing to disclose.   |
| Tara Lin          | Speaker         | Aptevo, Astellas Pharma, Bio-Path Holdings, Cleave Rese   | earch Funding: Leukemia &<br>phoma Society | Research FundingAptevo, Astellas Pharma, Bio-Path Holdings, Cleave, J  |
| Yazan Madanat     | Speaker         | Jazz, Trovagene Lymp<br>GERON, GSK, Kura Oncology, Morphosys, Novartis Meml<br>OncLive, Rigel pharmaceutical, Sierra Oncology, SOBbmr<br>Pharmaceuticals, Stemline Therapeutics | nbership on a Board or Advisory            | Trovagene<br>ConsultancyGERON, GSK, Kura Oncology<br>Membership on a Board or Advisory Committebovartis, Kura Oncology,<br>Stemline Therapeutics   |

| Kristen Sanfilippo                                 | Speaker                       | N/A   | Research FundingAmerican Cancer<br>Society: ACS IRG-18-158-61-04, ASH<br>Scholar Junior Faculty Research Awa<br>NIH NHLBI 1K01HL136893-01, NIH N<br>1R01HL166386-01<br>Consultancy Health Services Advisory   | d,  |
|--|-------------------------------|---|---|---|
| Nadine Shehata<br>Patricia A. Shi<br>Surbhi Sidana | Speaker<br>Speaker<br>Speaker | Agios, Ferring International, Janssen<br>Global Blood Therapeutics, Terumo BCT<br>Abbvie, Allogene, BMS, Kite, Janssen, Legend B<br>Magenta Therapeutics, Oncopeptides, Sanofi, Pfi<br>Takeda, BMS, Janssen, Magenta Therapeutics,      |   | Honoraria: Agios, Honoraria: Ferring International<br>Membership on a Board or Advisory Committee: Janssen<br>Research Funding: Global Blood Therapeutics, Terumo BCT<br>Research Funding: Allogene, BMS, Janssen, Magenta Therapeutics<br>ConsultancyAbbvie,BMS, Kite, Janssen, Legend Biotech, Magenta<br>Therapeutics, Oncopeptides, Sanofi, Pfizer, Takeda  |
| Natasha Szuber<br>Srinivas Tantravahi              | Speaker<br>Speaker            | Oncopeptides, Sanofi<br>Novartis<br>Karyopharm Therapeutics Inc, Incyte, Morphosys<br>AbbVie, CTI BioPharma, Novartis, Karyopharm<br>Therapeutics Inc, Incyte, Morphosys, AbbVie, CT<br>BioPharma, Novartis, Health Analytic Research L |   | Honoraria:Novartis<br>Consultancy/Karyopharm Therapeutics Inc, Incyte, MorphoSys, AbbVie, (<br>BioPharma, Novartis, Partnership for Health Analytic Research LLC<br>Membership on a Board or Advisory Committek aryopharm Therapeutics<br>Inc, Incyte, MorphoSys, AbbVie, CTI BioPharma, Novartis, Partnership for<br>Health Analytic Research LLC<br>Research Funding aryopharm Therapeutics Inc<br>Honoraria:Karyopharm Therapeutics Inc, Incyte, MorphoSys, AbbVie, CTI<br>BioPharma, Novartis, Partnership for Health Analytic Research LLC |
| Justin Watts                                       | Speaker                       | Attivare, Aptose, BMS, Daiichi Sankyo, Immune<br>Systems Key, Ltd., Rafael Pharma, Reven Pharm<br>^ Œ À ] Œ U d I   | a, Rigel,   | Consultancy: Attivare, Rigel, Servier<br>Membership on a Board or Advisory CommitteAptose, BMS, Daiichi<br>Sankyo, Rafael Pharma, Reven Pharma, Rigel, Servier, Takeda<br>Research Fundingmmune Systems Key, Ltd., Rigel, Takeda  |
| Angela Weyand                                      | Speaker                       | Bayer, Genentech, Novo Nordisk, Sanofi, Takeda<br>Pfizer  | , S   | ConsultancyBayer, Genentech, Novo Nordisk, Sanofi, Takeda<br>Membership on a Board or Advisory Committe8park<br>Research Funding: Novo Nordisk, Pfizer, Sanofi, Takeda  |
| Neil Zakai   | Planner/Speaker               | Na  | Membership on a Board or Advisory<br>Committee: American Heart Associatio<br>Editorial Board of Research and Pract<br>of Thrombosis and Haemostasis,<br>Hemophilia and Thrombosis Research<br>Society, International Society of<br>Thrombosis and Haemostasis<br>Research Funding ational Institutes o<br>Health, Centers for Disease Control an<br>Prevention<br>Honoraria: American Society of<br>Hematology, International Society of<br>Thrombosis and Haemostasis<br>Employment: University of Vermont<br>College of Medicine, University of<br>Vermont Medical Center | Nothing to disclose   |
| Alison Walker                                      | Planner                       | Geron, Newave, Novartis   | Membership on a Board or Advisory<br>Committee:   |   |